Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells.

Biomolecules & therapeutics

Shin DW, Kwon YJ, Ye DJ, Baek HS, Lee JE, Chun YJ.
PMID: 27956714
Biomol Ther (Seoul). 2017 Mar 01;25(2):177-185. doi: 10.4062/biomolther.2016.223.

Auranofin has been developed as antirheumatic drugs, which is currently under clinical development for the treatment of chronic lymphocytic leukemia. Previous report showed that auranofin induced apoptosis by enhancement of annexin A5 expression in PC-3 cells. To understand the...

Cite
Shin DW, Kwon YJ, Ye DJ, et al. Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells. Biomol Ther (Seoul). 2017;25(2):177-185doi: 10.4062/biomolther.2016.223.
Shin, D. W., Kwon, Y. J., Ye, D. J., Baek, H. S., Lee, J. E., & Chun, Y. J. (2017). Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells. Biomolecules & therapeutics, 25(2), 177-185. https://doi.org/10.4062/biomolther.2016.223
Shin, Dong-Won, et al. "Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells." Biomolecules & therapeutics vol. 25,2 (2017): 177-185. doi: https://doi.org/10.4062/biomolther.2016.223
Shin DW, Kwon YJ, Ye DJ, Baek HS, Lee JE, Chun YJ. Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells. Biomol Ther (Seoul). 2017 Mar 01;25(2):177-185. doi: 10.4062/biomolther.2016.223. PMID: 27956714; PMCID: PMC5340543.
Copy Download .nbib Format: NLM
Structure and function of plasminogen activator inhibitor-2.

International journal of oncology

Jensen P.
PMID: 21528247
Int J Oncol. 1997 Sep;11(3):557-70.

Serine proteinase inhibitors (serpins) are well known regulators of extracellular proteolytic pathways. A recently identified group of intracellular serpins of mammalian and viral origin, designated ovalbumine-like serpins, modify intracellular proteolytic pathways involved in the regulation of apoptosis and inflammation....

Cite
Jensen P. Structure and function of plasminogen activator inhibitor-2. Int J Oncol. 1997;11(3):557-70
Jensen, P. (1997). Structure and function of plasminogen activator inhibitor-2. International journal of oncology, 11(3), 557-70.
Jensen, P. "Structure and function of plasminogen activator inhibitor-2." International journal of oncology vol. 11,3 (1997): 557-70.
Jensen P. Structure and function of plasminogen activator inhibitor-2. Int J Oncol. 1997 Sep;11(3):557-70. PMID: 21528247.
Copy Download .nbib Format: NLM
Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

International journal of molecular sciences

Pechlivani N, Kearney KJ, Ajjan RA.
PMID: 34830419
Int J Mol Sci. 2021 Nov 21;22(22). doi: 10.3390/ijms222212537.

Thrombus formation remains a major cause of morbidity and mortality worldwide. Current antiplatelet and anticoagulant therapies have been effective at reducing vascular events, but at the expense of increased bleeding risk. Targeting proteins that interact with fibrinogen and which...

Cite
Pechlivani N, Kearney KJ, Ajjan RA. Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. Int J Mol Sci. 2021;22(22)doi: 10.3390/ijms222212537.
Pechlivani, N., Kearney, K. J., & Ajjan, R. A. (2021). Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. International journal of molecular sciences, 22(22), . https://doi.org/10.3390/ijms222212537
Pechlivani, Nikoletta, et al. "Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics." International journal of molecular sciences vol. 22,22 (2021). doi: https://doi.org/10.3390/ijms222212537
Pechlivani N, Kearney KJ, Ajjan RA. Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. Int J Mol Sci. 2021 Nov 21;22(22). doi: 10.3390/ijms222212537. PMID: 34830419; PMCID: PMC8625824.
Copy Download .nbib Format: NLM
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.

International journal of oncology

Maeda K, Chung Y, Sawada T, Ogawa Y, Onoda N, Nakata B, Kato Y, Sowa M.
PMID: 21544388
Int J Oncol. 1996 Mar;8(3):499-503. doi: 10.3892/ijo.8.3.499.

Urokinase-type plasminogen activator (UPA) is a serine protease implicated in cancer invasion and metastasis. There are at least two kinds of specific inhibitor which act on UPA: plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2). It has been...

Cite
Maeda K, Chung Y, Sawada T, et al. Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. Int J Oncol. 1996;8(3):499-503doi: 10.3892/ijo.8.3.499.
Maeda, K., Chung, Y., Sawada, T., Ogawa, Y., Onoda, N., Nakata, B., Kato, Y., & Sowa, M. (1996). Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. International journal of oncology, 8(3), 499-503. https://doi.org/10.3892/ijo.8.3.499
Maeda, K, et al. "Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma." International journal of oncology vol. 8,3 (1996): 499-503. doi: https://doi.org/10.3892/ijo.8.3.499
Maeda K, Chung Y, Sawada T, Ogawa Y, Onoda N, Nakata B, Kato Y, Sowa M. Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. Int J Oncol. 1996 Mar;8(3):499-503. doi: 10.3892/ijo.8.3.499. PMID: 21544388.
Copy Download .nbib Format: NLM
A comparative proteomics study of a synovial cell line stimulated with TNF-α.

FEBS open bio

Shibasaki S, Karasaki M, Aburaya S, Morisaka H, Takeda Y, Aoki W, Kitano S, Kitano M, Ueda M, Sano H, Iwasaki T.
PMID: 27419047
FEBS Open Bio. 2016 Mar 31;6(5):418-24. doi: 10.1002/2211-5463.12049. eCollection 2016 May.

To elucidate the pathogenesis of rheumatoid arthritis (RA), we used proteomic analysis to determine the protein profile in a synovial cell line, MH7A, established from patients with RA. Proteins were extracted from MH7A cells that were or were not...

Cite
Shibasaki S, Karasaki M, Aburaya S, et al. A comparative proteomics study of a synovial cell line stimulated with TNF-α. FEBS Open Bio. 2016;6(5):418-24doi: 10.1002/2211-5463.12049.
Shibasaki, S., Karasaki, M., Aburaya, S., Morisaka, H., Takeda, Y., Aoki, W., Kitano, S., Kitano, M., Ueda, M., Sano, H., & Iwasaki, T. (2016). A comparative proteomics study of a synovial cell line stimulated with TNF-α. FEBS open bio, 6(5), 418-24. https://doi.org/10.1002/2211-5463.12049
Shibasaki, Seiji, et al. "A comparative proteomics study of a synovial cell line stimulated with TNF-α." FEBS open bio vol. 6,5 (2016): 418-24. doi: https://doi.org/10.1002/2211-5463.12049
Shibasaki S, Karasaki M, Aburaya S, Morisaka H, Takeda Y, Aoki W, Kitano S, Kitano M, Ueda M, Sano H, Iwasaki T. A comparative proteomics study of a synovial cell line stimulated with TNF-α. FEBS Open Bio. 2016 Mar 31;6(5):418-24. doi: 10.1002/2211-5463.12049. eCollection 2016 May. PMID: 27419047; PMCID: PMC4856420.
Copy Download .nbib Format: NLM
Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling.

Data in brief

Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE.
PMID: 27284570
Data Brief. 2016 May 21;8:98-104. doi: 10.1016/j.dib.2016.05.026. eCollection 2016 Sep.

Data is presented that was utilized as the basis for Bayesian network modeling of influence pathways focusing on the central role of a polymorphism of plasminogen activator inhibitor-2 (PAI-2) on recurrent cardiovascular disease risk in patients with high levels...

Cite
Corsetti JP, Salzman P, Ryan D, et al. Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling. Data Brief. 2016;8:98-104doi: 10.1016/j.dib.2016.05.026.
Corsetti, J. P., Salzman, P., Ryan, D., Moss, A. J., Zareba, W., & Sparks, C. E. (2016). Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling. Data in brief, 898-104. https://doi.org/10.1016/j.dib.2016.05.026
Corsetti, James P, et al. "Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling." Data in brief vol. 8 (2016): 98-104. doi: https://doi.org/10.1016/j.dib.2016.05.026
Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE. Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling. Data Brief. 2016 May 21;8:98-104. doi: 10.1016/j.dib.2016.05.026. eCollection 2016 Sep. PMID: 27284570; PMCID: PMC4887557.
Copy Download .nbib Format: NLM
Plasminogen.

Brain research. Gene expression patterns

Sharon R, Abramovitz R, Miskin R.
PMID: 15018812
Brain Res Gene Expr Patterns. 2001 Aug;1(1):5-11. doi: 10.1016/s1567-133x(00)00003-x.

Plasminogen activator inhibitor-2 (PAI-2) specifically inhibits plasminogen activators, extracellular fibrinolytic serine proteases that are also implicated in brain plasticity and toxicity. Primarily localized intracellularly, PAI-2 is thought to also counteract apoptosis mediated by a currently undefined intracellular protease. Here...

Cite
Sharon R, Abramovitz R, Miskin R. Plasminogen. Brain Res Gene Expr Patterns. 2001;1(1):5-11doi: 10.1016/s1567-133x(00)00003-x.
Sharon, R., Abramovitz, R., & Miskin, R. (2001). Plasminogen. Brain research. Gene expression patterns, 1(1), 5-11. https://doi.org/10.1016/s1567-133x(00)00003-x
Sharon, R, et al. "Plasminogen." Brain research. Gene expression patterns vol. 1,1 (2001): 5-11. doi: https://doi.org/10.1016/s1567-133x(00)00003-x
Sharon R, Abramovitz R, Miskin R. Plasminogen. Brain Res Gene Expr Patterns. 2001 Aug;1(1):5-11. doi: 10.1016/s1567-133x(00)00003-x. PMID: 15018812.
Copy Download .nbib Format: NLM
Proteome analysis of human Wharton's jelly cells during in vitro expansion.

Proteome science

Angelucci S, Marchisio M, Di Giuseppe F, Pierdomenico L, Sulpizio M, Eleuterio E, Lanuti P, Sabatino G, Miscia S, Di Ilio C.
PMID: 20346146
Proteome Sci. 2010 Mar 26;8:18. doi: 10.1186/1477-5956-8-18.

BACKGROUND: The human umbilical cord contains mucoid connective tissue and fibroblast-like cells. These cells named Wharton's jelly cells, (WJCs) display properties similar to mesenchymal stem cells therefore representing a rich source of primitive cells to be potentially used in...

Cite
Angelucci S, Marchisio M, Di Giuseppe F, et al. Proteome analysis of human Wharton's jelly cells during in vitro expansion. Proteome Sci. 2010;8:18doi: 10.1186/1477-5956-8-18.
Angelucci, S., Marchisio, M., Di Giuseppe, F., Pierdomenico, L., Sulpizio, M., Eleuterio, E., Lanuti, P., Sabatino, G., Miscia, S., & Di Ilio, C. (2010). Proteome analysis of human Wharton's jelly cells during in vitro expansion. Proteome science, 818. https://doi.org/10.1186/1477-5956-8-18
Angelucci, Stefania, et al. "Proteome analysis of human Wharton's jelly cells during in vitro expansion." Proteome science vol. 8 (2010): 18. doi: https://doi.org/10.1186/1477-5956-8-18
Angelucci S, Marchisio M, Di Giuseppe F, Pierdomenico L, Sulpizio M, Eleuterio E, Lanuti P, Sabatino G, Miscia S, Di Ilio C. Proteome analysis of human Wharton's jelly cells during in vitro expansion. Proteome Sci. 2010 Mar 26;8:18. doi: 10.1186/1477-5956-8-18. PMID: 20346146; PMCID: PMC2867805.
Copy Download .nbib Format: NLM
Plasminogen activators and inhibitors in ovarian adenocarcinomas.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

O'Toole S, McGuinness E, Sheppard B, Bonnar J.
PMID: 11240744
Int J Gynecol Cancer. 1999 Jan;9(1):61-66. doi: 10.1046/j.1525-1438.1999.09893.x.

The fibrinolytic process was examined in cultures from malignant epithelial ovarian tumors and compared to normal ovarian tissue. The fibrinolytic enzymes, urokinase plasminogen activator (uPA) antigen and activity, tissue plasminogen activator (tPA) antigen and activity, plasminogen activator inhibitor 1...

Cite
O'Toole S, McGuinness E, Sheppard B, et al. Plasminogen activators and inhibitors in ovarian adenocarcinomas. Int J Gynecol Cancer. 1999;9(1):61-66doi: 10.1046/j.1525-1438.1999.09893.x.
O'Toole, S., McGuinness, E., Sheppard, B., & Bonnar, J. (1999). Plasminogen activators and inhibitors in ovarian adenocarcinomas. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 9(1), 61-66. https://doi.org/10.1046/j.1525-1438.1999.09893.x
O'Toole, S., et al. "Plasminogen activators and inhibitors in ovarian adenocarcinomas." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 9,1 (1999): 61-66. doi: https://doi.org/10.1046/j.1525-1438.1999.09893.x
O'Toole S, McGuinness E, Sheppard B, Bonnar J. Plasminogen activators and inhibitors in ovarian adenocarcinomas. Int J Gynecol Cancer. 1999 Jan;9(1):61-66. doi: 10.1046/j.1525-1438.1999.09893.x. PMID: 11240744.
Copy Download .nbib Format: NLM
PP047. Fetal gender specific differences in markers of placentation and maternal adaptation to pregnancy - The generation R study.

Pregnancy hypertension

Brown Z, Timmermans S, Steegers E.
PMID: 26105904
Pregnancy Hypertens. 2013 Apr;3(2):84. doi: 10.1016/j.preghy.2013.04.074. Epub 2013 Jun 06.

INTRODUCTION: Evidence indicates a gender specific interaction between the mother, placenta and fetus in which maternal adaptation to pregnancy and outcome partly depends on fetal gender.OBJECTIVES: This study assesses fetal gender specific differences in placental biomarkers and uteroplacental vascular...

Cite
Brown Z, Timmermans S, Steegers E. PP047. Fetal gender specific differences in markers of placentation and maternal adaptation to pregnancy - The generation R study. Pregnancy Hypertens. 2013;3(2):84doi: 10.1016/j.preghy.2013.04.074.
Brown, Z., Timmermans, S., & Steegers, E. (2013). PP047. Fetal gender specific differences in markers of placentation and maternal adaptation to pregnancy - The generation R study. Pregnancy hypertension, 3(2), 84. https://doi.org/10.1016/j.preghy.2013.04.074
Brown, Zoe, et al. "PP047. Fetal gender specific differences in markers of placentation and maternal adaptation to pregnancy - The generation R study." Pregnancy hypertension vol. 3,2 (2013): 84. doi: https://doi.org/10.1016/j.preghy.2013.04.074
Brown Z, Timmermans S, Steegers E. PP047. Fetal gender specific differences in markers of placentation and maternal adaptation to pregnancy - The generation R study. Pregnancy Hypertens. 2013 Apr;3(2):84. doi: 10.1016/j.preghy.2013.04.074. Epub 2013 Jun 06. PMID: 26105904.
Copy Download .nbib Format: NLM
Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Sadlonova A, Bowe DB, Novak Z, Mukherjee S, Duncan VE, Page GP, Frost AR.
PMID: 19308679
Cancer Microenviron. 2009 Dec;2(1):9-21. doi: 10.1007/s12307-008-0017-0. Epub 2009 Mar 18.

Stromal fibroblasts influence the behavior of breast epithelial cells. Fibroblasts derived from normal breast (NAF) inhibit epithelial growth, whereas fibroblasts from breast carcinomas (CAF) have less growth inhibitory capacity and can promote epithelial growth. We sought to identify molecules...

Cite
Sadlonova A, Bowe DB, Novak Z, et al. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron. 2009;2(1):9-21doi: 10.1007/s12307-008-0017-0.
Sadlonova, A., Bowe, D. B., Novak, Z., Mukherjee, S., Duncan, V. E., Page, G. P., & Frost, A. R. (2009). Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2(1), 9-21. https://doi.org/10.1007/s12307-008-0017-0
Sadlonova, Andrea, et al. "Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 2,1 (2009): 9-21. doi: https://doi.org/10.1007/s12307-008-0017-0
Sadlonova A, Bowe DB, Novak Z, Mukherjee S, Duncan VE, Page GP, Frost AR. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron. 2009 Dec;2(1):9-21. doi: 10.1007/s12307-008-0017-0. Epub 2009 Mar 18. PMID: 19308679; PMCID: PMC2787925.
Copy Download .nbib Format: NLM
New Target Genes for Tumor-derived Soluble Factors in Primary Monocytes.

Cancer genomics & proteomics

Hofmann T, Schmitt B, Mack B, Lang S, Gires O, Zeidler R.
PMID: 31394681
Cancer Genomics Proteomics. 2004 Mar-Apr;1(2):167-176. Epub 2004 Mar 01.

BACKGROUND: Tumor cells have developed several strategies to escape the immune system. One of these strategies consists of the secretion of immunosuppressive factors like interleukin-10 or prostaglandin E2 (PGEMATERIALS AND METHODS: In order to identify new target genes for...

Cite
Hofmann T, Schmitt B, Mack B, et al. New Target Genes for Tumor-derived Soluble Factors in Primary Monocytes. Cancer Genomics Proteomics. 2004;1(2):167-176
Hofmann, T., Schmitt, B., Mack, B., Lang, S., Gires, O., & Zeidler, R. (2004). New Target Genes for Tumor-derived Soluble Factors in Primary Monocytes. Cancer genomics & proteomics, 1(2), 167-176.
Hofmann, Tanja, et al. "New Target Genes for Tumor-derived Soluble Factors in Primary Monocytes." Cancer genomics & proteomics vol. 1,2 (2004): 167-176.
Hofmann T, Schmitt B, Mack B, Lang S, Gires O, Zeidler R. New Target Genes for Tumor-derived Soluble Factors in Primary Monocytes. Cancer Genomics Proteomics. 2004 Mar-Apr;1(2):167-176. Epub 2004 Mar 01. PMID: 31394681.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries